Theriva Biologics (TOVX) EBT (2010 - 2026)
Theriva Biologics (TOVX) posted quarterly EBT of -$2.0 million for Q1 2026, up 52.73% year-over-year from -$1.3 million in Q1 2025, and down 2.4% quarter-over-quarter from -$2.0 million in Q4 2025.
Theriva Biologics (TOVX) EBT (2010 - 2026) Analysis & Trends
Theriva Biologics (TOVX) has reported EBT for 17 consecutive years, with -$2.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT rose 52.73% year-over-year to -$2.0 million; the TTM figure through Mar 2026 stood at -$21.5 million (up 13.52% YoY), while the FY2025 annual figure was -$23.7 million, up 7.46% from the prior year.
- EBT fell to -$2.0 million in Q1 2026 per TOVX's latest filing, from -$2.0 million in the prior quarter.
- Across five years, EBT topped out at -$2.0 million in Q4 2025 and bottomed at -$13.1 million in Q2 2025.
- Historically, EBT has averaged -$5.4 million across 5 years, with a median of -$4.8 million in 2022.
- Annual changes were most pronounced in 2024 — EBT sank 101.72% — and 2025, when it jumped 55.12%.
- Theriva Biologics' EBT stood at -$7.0 million in 2022, then rose by 15.62% to -$5.9 million in 2023, then grew by 24.74% to -$4.4 million in 2024, then surged by 55.12% to -$2.0 million in 2025, then decreased by 2.4% to -$2.0 million in 2026.
- Business Quant data shows TOVX's EBT at -$2.0 million in Q1 2026, -$2.0 million in Q4 2025, and -$4.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.77 Bn | 131.91 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 65.36 Bn | 60.17 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 59.60 Bn | 54.47 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 177.81 Mn |
| 7 | BioNTech SE | 28.13 Bn | 9.73 Bn | 668.28 Mn | -264.70 Mn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | -11.37 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 81.49 Mn |
| 10 | Theriva Biologics | 10.97 Mn | 10.97 Mn | - | -3.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.22 Mn |
| Mar 31, 2026 | -2.04 Mn |
| Dec 31, 2025 | -2.00 Mn |
| Sep 30, 2025 | -4.36 Mn |
| Jun 30, 2025 | -13.06 Mn |
| Mar 31, 2025 | -4.32 Mn |
| Dec 31, 2024 | -4.45 Mn |
| Sep 30, 2024 | -7.73 Mn |
| Jun 30, 2024 | -8.32 Mn |
| Mar 31, 2024 | -5.17 Mn |
| Dec 31, 2023 | -5.91 Mn |
| Sep 30, 2023 | -3.83 Mn |
| Jun 30, 2023 | -5.44 Mn |
| Mar 31, 2023 | -4.81 Mn |
| Dec 31, 2022 | -7.00 Mn |
| Sep 30, 2022 | -4.83 Mn |
| Jun 30, 2022 | -5.01 Mn |
| Mar 31, 2022 | -4.27 Mn |
| Dec 31, 2021 | -5.34 Mn |
| Sep 30, 2021 | -3.41 Mn |